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This study was conducted to determine the effects of omega-3 fatty acids and vitamin E co-
supplementation on gene expression of lipoprotein(a) (Lp[a]) and oxidized low-density lipoprotein
(Ox-LDL), lipid proﬁles and biomarkers of oxidative stress in women with polycystic ovary syndrome
(PCOS). This randomized double-blind, placebo-controlled trial was done on 68 women diagnosed with
PCOS according to the Rotterdam criteria aged 18e40 years old. Participants were randomly assigned into
two groups to receive either 1000 mg omega-3 fatty acids from ﬂaxseed oil containing 400 mg a-
Linolenic acid plus 400 IU vitamin E supplements (n ¼ 34) or placebo (n ¼ 34) for 12 weeks. Lp(a) and
Ox-LDL mRNA levels were quantiﬁed in peripheral blood mononuclear cells of PCOS womenwith RT-PCR
method. Lipid proﬁles and biomarkers of oxidative stress were quantiﬁed at the beginning of the study
and after 12-week intervention. Quantitative results of RT-PCR demonstrated that compared with the
placebo, omega-3 fatty acids and vitamin E co-supplementation downregulated expressed levels of Lp(a)
mRNA (P < 0.001) and Ox-LDL mRNA (P < 0.001) in peripheral blood mononuclear cells of women with
PCOS. In addition, compared to the placebo group, omega-3 fatty acids and vitamin E co-
supplementation resulted in a signiﬁcant decrease in serum triglycerides (22.1 ± 22.3
vs. þ7.7 ± 23.6 mg/dL, P < 0.001), VLDL- (4.4 ± 4.5 vs. þ1.5 ± 4.7 mg/dL, P < 0.001), total- (20.3 ± 16.6
vs. þ12.2 ± 26.1 mg/dL, P < 0.001), LDL- (16.7 ± 15.3 vs. þ11.9 ± 26.1 mg/dL, P < 0.001) and total-/HDL-
cholesterol (0.5 ± 0.6 vs. þ0.4 ± 0.8, P < 0.001). There were a signiﬁcant increase in plasma total
antioxidant capacity (þ89.4 ± 108.9 vs. þ5.9 ± 116.2 mmol/L, P ¼ 0.003) and a signiﬁcant decrease in
malondialdehyde levels (0.3 ± 0.4 vs. -0.008 ± 0.6 mmol/L, P ¼ 0.01) by combined omega-3 fatty acids
and vitamin E intake compared with the placebo group. Overall, omega-3 fatty acids and vitamin E co-
supplementation for 12 weeks in PCOS women signiﬁcantly improved gene expression of Lp(a) and Ox-
LDL, lipid proﬁles and biomarkers of oxidative stress.
© 2016 Elsevier Ireland Ltd. All rights reserved.rved.1. Introduction
Polycystic ovary syndrome (PCOS) is a common metabolic and
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depending on the criteria used (Conway et al., 2014). Dislipidemia
especially decreased HDL-cholesterol and increased triglyceride
concentrations are certainly the most prevalent and persistent
among cardiovascular risk factors in women with PCOS (Macut
et al., 2013). According to the National Cholesterol Education Pro-
gram guidelines, about 70% of womenwith PCOS have borderline or
high lipid concentrations (Legro et al., 2001). In addition, few
studies have reported that oxidized low-density lipoprotein (Ox-
LDL) levels as a marker of altered lipid metabolism were signiﬁ-
cantly higher in untreated PCOS patients than controls (Macut et al.,
2006; Carlioglu et al., 2014). Elevated levels of Ox-LDL are associ-
ated with the initiation and progression of atherosclerosis (Ehara
et al., 2001). PCOS is also associated with oxidative stress in
which increased production of free radicals and reactive oxygen
species (ROS) are followed by decreased total antioxidant levels
(Gonzalez et al., 2006). Oxidative stress may play a role in the
dysregulation of the theca-interstitial compartment and the
development of cardiovascular disease (Duleba et al., 2004; Youn
et al., 2014).
The tendency towards increasing the extent of plaque formation
in the third decade of life in PCOS patients suggests that risk factor
modiﬁcation in the population should be initiated almost in the
second decade of life (Macut et al., 2013). Recently, few studies
reported that omega-3 fatty acids and vitamin E administration can
be associated with improved endocrine and metabolic character-
istics in women with PCOS (Liepa et al., 2008; Mohammadi et al.,
2012). In a study (Mohammadi et al., 2012), was observed that
4 g/day omega-3 fatty acids intake for 8 weeks decreased the risk
for cardiovascular disease through the reduction in some lipids
ratio among PCOS patients. In addition, the beneﬁcial effects of
omega-3 fatty acids and vitamin E co-supplementation on serum
enzymatic antioxidants were previously reported among patients
with type 2 diabetes mellitus (T2DM) (Sarbolouki et al., 2010).
However, no signiﬁcant effect in biomarkers of oxidative stress was
observed following supplementation with omega-3 fatty acids
among healthy young adults for 4 weeks (Cunnane et al., 1995) and
vitamin E among hemodialysis patients (Ahmadi et al., 2013).
Co-supplementation of omega-3 fatty acids and vitamin E may
work better than a single supplementation alone. In addition,
omega-3 fatty acids and vitamin E co-supplementation might have
a strong synergistic effect on lipid proﬁles and biomarkers of
oxidative stress. Our previous study have shown that omega-3 fatty
acids and vitamin E co-supplementation for 6 weeks among pa-
tients with gestational diabetes (GDM) had the beneﬁcial effects on
lipid proﬁles (Taghizadeh et al., 2016). Furthermore, joint omega-3
fatty acids and vitamin E administration might have a strong syn-
ergistic effect on adiponectin levels and peroxisome proliferator-
activated receptor gamma (PPARg) (Ramezani et al., 2015). PPAR-
g regulates expressed levels of several genes encoding proteins
involved in adipocyte differentiation, fatty acid storage and glucose
metabolism (Grindﬂek et al., 2000). Reduced expression of PPARg
causes insulin resistance (Kursawe et al., 2010), which in turn is
associated with the pathogenesis of dyslipidemia in women with
PCOS (El-Mazny et al., 2010). The aim of the current study was to
evaluate the effects of omega-3 fatty acids and vitamin E co-
supplementation on gene expression of lipoprotein(a) (Lp[a]) and
Ox-LDL, lipid proﬁles and biomarkers of oxidative stress in these
patients.
2. Materials and methods
2.1. Participants
In the current study, 68 patients with PCOS aged 18e40 yearsold referred to the Research and Clinical Center for Infertility and
the Naghavi Clinic in Kashan, Iran, between December 2015 and
February 2016 were included. Diagnosis of PCOS was done ac-
cording to the Rotterdam criteria (2004): those with the two of the
following criteria were considered as having PCOS: 1) oligo- and/or
anovulation (deﬁned as delayed menses>35 days or<8 sponta-
neous hemorrhagic episodes/year), 2) clinical [hirsutism using
modiﬁed Ferriman-Gallwey (mFG) score of8] (2004) and/or
biochemical signs of hyperandrogenism (Huang et al., 2010) and 3)
polycystic ovaries (12 or more follicles in each ovary measuring
2e9 mm in diameter, and/or increased ovarian volume>10 ml3)
(Rotterdam criteria, 2004). Study exclusion criteria included:
pregnancy, using oral contraceptive pills (OCP), elevated levels of
prolactin, thyroid disorder, endocrine diseases including diabetes
or impaired glucose tolerance and gastrointestinal problems.
2.2. Ethics statements
The current study was conducted in accordance with the
Declaration of Helsinki and informed consent was obtained from all
participants. The research was approved by the ethics committee of
Kashan University of Medical Sciences (KUMS) and was recorded in
the Iranian website for registration of clinical trials (http://www.
irct.ir:IRCT201601085623N67).
2.3. Study design
At the onset of the study, all individuals were matched accord-
ing to age, phenotypes A (14 patients in each group) and D (20
patients in each group) of PCOS, and body mass index (BMI) at the
study baseline. Phenotypes A and D were deﬁned as olig-
anovulation þ hyperandrogenism þ polycystic ovary morphology
and olig-anovulation þ polycystic ovary morphology, respectively
(Jamil et al., 2015). The present studywas a prospective randomized
double-blind placebo-controlled clinical trial. Participants were
then randomly divided into two groups to receive either omega-3
fatty acids plus vitamin E supplements (n ¼ 34) or placebo
(n¼ 34) for 12weeks. All participants were takingmetformin tablet
at the initial dose of 500 mg, which was increased in a stepwise
manner during the ﬁrst 3 weeks to a total of 1500 mg/day
(Weerakiet et al., 2004). Participants were requested not to change
their ordinary physical activity and not to take any nutritional
supplements during the 12-week trial. All participants completed
3-day food records and three physical activity records at weeks 0, 3,
6, 9 and 12 of the intervention. Daily macro- and micro-nutrient
dietary intakes were analyzed by nutritionist IV software (First
Databank, San Bruno, CA). In the current study, physical activity
was described as metabolic equivalents (METs) in hours per day. To
determine the METs for each patient, we multiplied the times (in
hour per day) reported for each physical activity by its related METs
coefﬁcient by standard tables (Ainsworth et al., 2000).
2.4. Intervention
In the treatment group, persons received 1000 mg omega-3
fatty acids from ﬂaxseed oil containing 400 mg a-Linolenic acid
plus 400 IU vitamin E supplements for 12 weeks. Supplements and
placebos capsules were similar in shape and size andmanufactured
by Barij Essence (Kashan, Iran).
2.5. Treatment adherence
Every four weeks, persons were given enough supplements to
last until 3 days after their next scheduled visit and were instructed
to return all the unused supplements at each visit. Participants
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termediate evaluation and an ulcer debridement. To evaluate the
compliance the remaining supplements were counted and sub-
tracted from the amount of supplements provided to the partici-
pants. To increase compliance, all patients received short messages
on their cell phones every day to remind them about taking the
capsules.
2.6. Assessment of anthropometric measures
Weight and height of participants were determined in an
overnight fasting status using a standard scale (Seca, Hamburg,
Germany) at the beginning of the study and after 12-weeks’
intervention. BMI was calculated as weight in kg divided by height
in meters squared. All anthropometric measures were done by a
trained staff at the gynecology clinic.
2.7. Assessment of outcomes
In our study, gene expression of Lp(a) and Ox-LDL, and bio-
markers of oxidative stress were considered as the primary
outcome, and body weight and changes in clinical characteristics of
hyperandrogenism were considered as the secondary outcomes.
2.8. Isolation of lymphocyte cells
At ﬁrst, 10 mL blood samples were obtained from participants at
the onset of the study and 12 weeks after intervention. Then,
lymphocyte cells were extracted from blood samples of women
with PCOS using a 50% percoll (Sigma-Aldrich, Dorset, UK) gradient.
Thus, for preparing a stock isotonic percoll solution, osmolity of the
solution was adjusted by adding 1 part of 10 x concentrated cell
culture medium into the 9 parts of percoll. Osmolality of the stock
solution was checked by osmometer model 3300 (LabX, EI Cajon,
USA). Solution of stock isotonic percoll (SIP) was diluted by adding
normal cell culture medium. The cells of lymphocytes which were
at the interface of percoll and serum were removed by using a
pasteur pipette and washed a few times with phosphate buffer
saline (PBS). Samples were taken for cell count and viability testing
by trypan blue, RNA and DNA extraction.
2.9. Total RNA extraction
In order to RNA extraction, the RNXplus kit (Cinnacolon, Tehran,
Iran) was used. Total RNA extraction from all prepared samples was
done as recommended protocol by manufacture. After preparation
of homogenate, the cells powder was harvested and re-suspended
in 1 ml of RNAXplus reagent in a clean RNase-free tube. After in-
cubation for 5 min at room temperature, the sample was pipetted
and subsequently treatedwith addition of 200 ml of chloroform. The
mixture incubated at room temperature for 5 min after shaking
rigorously for 15 s. The mixture was centrifuged at 12,000 g for
15 min and the aqueous phase containing the RNA was transferred
to a clean RNase-free tube. The total RNA was precipitated at room
temperature for 15 min. The pellet including total RNAwas washed
by using 75% ethanol and centrifuge at 7500 g for 8 min. After
drying ethanol, the RNA pellet re-suspended in 50 ml or less of TE
buffer. The concentration of total RNA was calculated based on OD
260/280 ration measurements as a means to means to address
purity of RNA. To conﬁrm the integrity of extracted RNA, it was
electrophoresed. RNA suspension was frozen in 20 C until cDNA
making. Following the extraction of the total RNAs from each
sample, RNA quantiﬁcation were performed by UV spectropho-
tometer. Each samples OD 260/280 ratio between 1.7 and 2.1 was
intended that shows no contamination with both protein and DNA.2.10. First strand cDNA synthesis procedure
The ﬁrst strand cDNA synthesis can be performed as an indi-
vidual reaction or as a series of parallel reactions with different RNA
templates. Therefore, the reaction mixture can be provided by
merging reagents individually or a master mix can be prepared all
of the components except template RNA. Depending on the struc-
ture of RNA templates, separate steps for RNA denaturation and
primer annealing many improve RT-PCR results. The isolated RNA
was reverse transcribed to cDNA library using moloney murine
leukemia virus (MMLV) reverse transcriptase (RT). Reverse tran-
scription was performed with random primers.
2.11. Gene expression
Expressed levels of Lp(a) and Ox-LDL were evaluated by quan-
titative RT-PCR, using the LightCycler technology (Roche Di-
agnostics, Rotkreuz, Switzerland) with SYBR green detection and
Amplicon Kit (Table 1). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) primers were used as a loading control (forward:
AAGCTCATTTCCTGGTATGACAACG; reverse:
TCTTCCTCTTGTGCTCTTGCTGG). As template, approximately 50 ng
cDNA was applied in a quantitative real-time RT-PCR, and the sig-
nals were detected using a real-time PCR system. All reactions were
run in duplicates. All primers were designed using Primer Express
Software (Applied Biosystems) and Beacon designer software then,
purchased from Takaposizt Company- IRAN. Relative transcription
levels were calculated using Pffaﬁmethod or 2-DDCT. Normalization
of gene expression data is used to correct sample-to-sample vari-
ation. Starting material obtained from different individuals usually
varies in tissue mass or cell number, RNA integrity or quantity, or
experimental treatment. The ideal control gene should be
expressed in an unchanging fashion regardless of experimental
conditions, including different tissue or cell types, developmental
stage, or sample treatment. Because there is no one gene thatmeets
this criterion for every experimental condition, it is necessary to
validate the expression stability of a control gene for the speciﬁc
requirements of an experiment prior to its use for normalization.
Also, GAPDH gene (housekeeping gene) was used for
normalization.
2.12. Clinical assessments
Clinical assessments included determinations of hirsutism using
a mFG scoring system (Hatch et al., 1981), of acne score
(Kolodziejczyk et al., 2000) and of alopecia based on assessment
guidelines collated by Olsen et al. (Olsen et al., 2004) in the current
study. Acne was marked by a four-point scale: 0, no acne; 1, minor
acne on face; 2, moderate acne on face only; and 3, severe acne, face
and back or chest (Kolodziejczyk et al., 2000).
2.13. Biochemical assessment
Ten milliliters fasting blood samples were taken at the begin-
ning of the study and after 12-week intervention at Kashan refer-
ence laboratory in a fasting status and centrifuged to separate
serum. Then, the samples were stored at 80C before analysis.
Enzymatic kits (Pars Azmun, Tehran, Iran) were used to quantify
serum triglycerides, VLDL-, total-, LDL- and HDL-cholesterol con-
centrations. Total-/HDL-cholesterol ratio was calculated as total
cholesterol divided by HDL-cholesterol. All inter- and intra-assay
coefﬁcient variances (CVs) for lipid concentrations were less than
5%. Plasma total antioxidant capacity (TAC) concentrations were
determined by the method of ferric reducing antioxidant power
developed by Benzie and Strain (Benzie and Strain, 1996), total
Table 1
Speciﬁc primers used for real-time quantitative PCR.
Gene Primer Product size (bp) Annealing temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
Lp(a) F: GACACAGCACGTTCATTCCA 55 200
R: ACACCCCCCTACAATGCTTC
Ox-LDL F: ACTTACGGACAGACAGACAG 57 223
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; Lp(a), lipoprotein(a); Ox-LDL, oxidized low-density lipoprotein.
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et al (Beutler and Gelbart, 1985). and malondialdehyde (MDA)
concentrations were determined by the thiobarbituric acid reactive
substances spectrophotometric test (Janero, 1990). All inter- and
intra-assay CVs for TAC, GSH and MDA concentrations were less
than 5%. Commercial kits were used to quantify serum follicular-
stimulating hormone (FSH) and luteinizing hormone (LH) con-
centrations (Pars Azmun, Tehran, Iran). Inter- and intra-assay CVs
for FSH and LH measurements were less than 7%.
2.14. Sample size
Using a formula suggested for clinical trials, having 29 partici-
pants in each group were adequate while considering a type one
error (a) of 0.05 and type two error (b) of 0.20 (power ¼ 80%),
41.5 mg/dL as SD and 31.0 mg/dL as the mean distinction (d) of
triglycerides as the key variable (Taghizadeh et al., 2016). Assuming
5 dropouts in each group, the ﬁnal sample size was determined to
be 34 participants in each group.
2.15. Randomization
Randomization assignment was done by the use of computer-
generated random numbers. Randomization and allocation were
concealed from the researchers and patients until the ﬁnal analyses
were completed. The randomized allocation sequence, enrolling
participants and allocating them to interventions were conducted
by a trained midwife at the gynecology clinic.
2.16. Statistical methods
To evaluate whether the study variables had normally distrib-
uted or not, we used the Kolmogrov-Smirnov test. To detect dif-
ferences in anthropometric measures as well as in macro- and
micro-nutrient dietary intakes between the two groups, we
applied Student's t-test to independent samples. Differences in
proportions were evaluated by Chi square test or Fisher's exact
tests. To determine the effects of omega-3 fatty acids and vitamin E
co-supplementation on gene expression of Lp(a) and Ox-LDL, lipid
proﬁles and biomarkers of oxidative stress, we used one-way
repeated measures analysis of variance. To identify within-group
differences (pre- and post-supplementation), we used paired-
samples t-tests. Adjustment for changes in baseline values of
biochemical parameters, age and BMI at the baseline was per-
formed by analysis of covariance (ANCOVA) using general linear
models. The P-value of <0.05 were considered statistically signiﬁ-
cant. All statistical analyses used the Statistical Package for Social
Science version 18 (SPSS Inc., Chicago, Illinois, USA).
3. Results
Among participants in the combined omega-3 fatty acids and
vitamin E group, 3 patients [due to pregnancy (n ¼ 3)] and in theplacebo group, 2 patients [withdrawn for personal reasons (n ¼ 2)]
were excluded (Fig. 1). At the end, 68 patients with PCOS [omega-3
fatty acids plus vitamin E (n¼ 34) and placebo (n ¼ 34)] completed
the trial. However, as the analysis was based on the ITT principle, all
68 patients (34 in each group) were included in the ﬁnal analyses.
Mean age, height, weight and BMI at the baseline and end-of-
trial, alopecia and acne rate, and METs at the baseline and end-
of-trial were not statistically different between the two groups
(Table 2).
Based on the 3-day dietary records obtained at the baseline,
end-of-trial and throughout the trial, we found no signiﬁcant dif-
ference in mean dietary macro- and micro-nutrient intakes be-
tween the two groups (Table 3).
Quantitative results of RT-PCR demonstrated that compared
with the placebo, omega-3 fatty acids and vitamin E co-
supplementation downregulated expressed levels of Lp(a) mRNA
(P < 0.001) in peripheral blood mononuclear cells of PCOS women
(Fig. 2).
A signiﬁcant change in expressed levels of Ox-LDL mRNA
(P < 0.001) in peripheral blood mononuclear cells of PCOS women
following the supplementation of omega-3 fatty acids plus vitamin
E compared with the placebo (Fig. 3).
After 12 weeks of intervention, compared to the placebo group,
omega-3 fatty acids and vitamin E co-supplementation resulted in
a signiﬁcant decrease in serum triglycerides (22.1 ± 22.3
vs. þ7.7 ± 23.6 mg/dL, P < 0.001), VLDL- (4.4 ± 4.5
vs. þ1.5 ± 4.7 mg/dL, P < 0.001), total- (20.3 ± 16.6
vs. þ12.2 ± 26.1 mg/dL, P < 0.001), LDL- (16.7 ± 15.3
vs. þ11.9 ± 26.1 mg/dL, P < 0.001) and total-/HDL-cholesterol
(0.5 ± 0.6 vs. þ0.4 ± 0.8, P < 0.001) (Table 4). There were a sig-
niﬁcant increase in plasma TAC (þ89.4 ± 108.9
vs. þ5.9 ± 116.2 mmol/L, P ¼ 0.003) and a signiﬁcant decrease in
MDA levels (0.3 ± 0.4 vs. -0.008 ± 0.6 mmol/L, P ¼ 0.01) by com-
bined omega-3 fatty acids and vitamin E intake compared with the
placebo group.We did not observe any signiﬁcant effect of omega-3
fatty acids and vitamin E co-supplementation on serum HDL-
cholesterol, plasma GSH, serum FSH and LH levels.
However, after adjustment for baseline values of biochemical
parameters, age and baseline BMI no signiﬁcant changes in our
ﬁndings occurred, except for plasma TAC (P ¼ 0.38) and MDA levels
(P ¼ 0.99) (Table 5).4. Discussion
In the current study, which to the best of our knowledge is the
ﬁrst of its kind, we evaluated effects of omega-3 fatty acids and
vitamin E co-supplementation on gene expression of Lp(a) and Ox-
LDL, lipid proﬁles and biomarkers of oxidative stress among pa-
tients with PCOS. We demonstrated that omega-3 fatty acids and
vitamin E co-supplementation for 12 weeks among PCOS women
had beneﬁcial effects on gene expression of Lp(a) and Ox-LDL,
serum triglycerides, VLDL-, total-, LDL- and total-/HDL-choles-
terol, plasma TAC and MDA levels; but it did not had any effect on
Randomized (n=68)
Allocated to placebo (n=34)
Lost to follow-up due to 
pregnancy (n=3)
Analyzed (n=34)
Allocated to intervention (n=34)
Lost to follow-up due to personal 
reasons (n=2)
Analyzed (n=34)
Assessed for eligibility (n=82)
Excluded (n=14) 
- Not meeting inclusion criteria (n=10) 






















Fig. 1. Summary of patient ﬂow diagram.
Table 2
General characteristics of study participants.
Placebo group (n ¼ 34) Omega-3 fatty acids plus vitamin E group (n ¼ 34) Pa
Age (y) 26.6 ± 5.6 24.9 ± 5.5 0.20
Height (cm) 163.3 ± 6.9 161.8 ± 6.2 0.35
Weight at study baseline (kg) 77.6 ± 18.2 74.1 ± 10.7 0.33
Weight at end-of-trial (kg) 77.4 ± 18.3 73.8 ± 10.8 0.31
Weight change (kg) 0.2 ± 1.1 0.3 ± 1.1 0.57
BMI at study baseline (kg/m2) 29.0 ± 6.5 28.4 ± 4.4 0.61
BMI at end-of-trial (kg/m2) 29.0 ± 6.5 28.2 ± 4.6 0.59
BMI change (kg/m2) 0.1 ± 0.4 0.1 ± 0.4 0.62
MET-h/day at study baseline 28.9 ± 2.3 29.4 ± 2.5 0.33
MET-h/day at end-of-trial 28.8 ± 2.3 29.5 ± 2.5 0.26
MET-h/day change 0.1 ± 0.8 0.1 ± 0.8 0.59
Decreased alopecia (%) 1 (4.5) 4 (22.2) 0.09b
Decreased acne (%) 2 (9.1) 5 (23.8) 0.19b
Data are means± SDs.
a Obtained from independent t-test. METs, metabolic equivalents.
b Obtained from Pearson Chi-square tests.
Table 3
Dietary intakes of study participants throughout the study.
Placebo group (n ¼ 34) Omega-3 fatty acids plus vitamin E group (n ¼ 34) Pa
Energy (kcal/d) 2511 ± 173 2524 ± 174 0.76
Carbohydrates (g/d) 347.9 ± 33.5 354.2 ± 47.0 0.53
Protein (g/d) 90.1 ± 11.7 91.1 ± 15.5 0.76
Fat (g/d) 88.0 ± 12.6 86.3 ± 13.8 0.59
SFAs (g/d) 26.4 ± 4.9 27.1 ± 5.5 0.44
PUFAs (g/d) 27.1 ± 6.7 27.7 ± 5.9 0.66
MUFAs (g/d) 24.4 ± 6.8 24.0 ± 5.5 0.78
Cholesterol (mg/d) 214.0 ± 106.0 215.3 ± 100.7 0.96
TDF (g/d) 20.0 ± 4.7 20.6 ± 4.9 0.62
Omega-3 (g/d) 1.0 ± 0.1 1.1 ± 0.2 0.30
Data are means± SDs.
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids; TDF, total dietary ﬁber.
a Obtained from independent t-test.
















Fig. 2. Effect of 12-week supplementation with omega-3 fatty acids plus vitamin E or
placebo on expression ratio of Lp(a) gene in blood mononuclear cells of PCOS women.
P value was obtained from independent samples Student's t-test. Data are















Fig. 3. Effect of 12-week supplementation with omega-3 fatty acids plus vitamin E or
placebo on expression ratio of Ox-LDL gene in blood mononuclear cells of PCOS
women. P value was obtained from independent samples Student's t-test. Data are
means ± standard deviation. Lp(a), lipoprotein(a); Ox-LDL, oxidized low-density li-
poprotein; PCOS, polycystic ovary syndrome.
Table 4
Lipid proﬁles and biomarkers of oxidative stress at the study baseline and after 12 weeks of the intervention in patients with polycystic ovary syndrome.
Placebo group (n ¼ 34) Omega-3 fatty acids plus vitamin E group (n ¼ 34) Pb
Baseline End-of-trial Change Pa Baseline End-of-trial Change Pa
Triglycerides (mg/dL) 120.6 ± 59.4 128.3 ± 72.6 7.7 ± 23.6 0.06 122.7 ± 61.7 100.6 ± 54.0 22.1 ± 22.3 <0.001 <0.001
VLDL-cholesterol (mg/dL) 24.1 ± 11.9 25.7 ± 14.5 1.5 ± 4.7 0.06 24.5 ± 12.3 20.1 ± 10.8 4.4 ± 4.5 <0.001 <0.001
Total cholesterol (mg/dL) 166.4 ± 29.2 178.6 ± 29.9 12.2 ± 26.1 0.01 181.8 ± 28.0 161.5 ± 31.4 20.3 ± 16.6 <0.001 <0.001
LDL-cholesterol (mg/dL) 92.9 ± 25.5 104.8 ± 26.3 11.9 ± 26.1 0.01 111.1 ± 26.5 94.4 ± 29.8 16.7 ± 15.3 <0.001 <0.001
HDL-cholesterol (mg/dL) 49.4 ± 8.1 48.1 ± 9.3 1.3 ± 6.3 0.24 46.2 ± 10.0 47.0 ± 9.5 0.8 ± 3.6 0.18 0.09
Total-/HDL-cholesterol 3.5 ± 0.8 3.9 ± 1.1 0.4 ± 0.8 0.007 4.1 ± 1.0 3.6 ± 0.9 0.5 ± 0.6 <0.001 <0.001
TAC (mmol/L) 969.5 ± 85.3 975.4 ± 98.0 5.9 ± 116.2 0.77 860.5 ± 101.0 949.9 ± 119.3 89.4 ± 108.9 <0.001 0.003
GSH (mmol/L) 511.8 ± 69.1 555.2 ± 62.4 43.3 ± 66.3 0.001 525.3 ± 84.1 544.8 ± 81.3 19.5 ± 39.3 0.007 0.07
MDA (mmol/L) 2.2 ± 0.5 2.2 ± 0.5 0.008 ± 0.6 0.93 2.9 ± 0.6 2.5 ± 0.6 0.3 ± 0.4 <0.001 0.01
FSH (IU/L) 7.9 ± 2.8 8.1 ± 3.2 0.2 ± 3.0 0.67 7.3 ± 2.5 7.2 ± 2.5 0.1 ± 3.5 0.86 0.68
LH (IU/L) 13.5 ± 13.3 11.4 ± 7.7 2.1 ± 13.3 0.35 11.0 ± 8.0 10.5 ± 8.9 0.5 ± 10.1 0.77 0.56
All values are means± SDs.
FSH, follicle-stimulating hormone; GSH, total glutathione; LH, luteinizing hormone; MDA, malondialdehyde; TAC, total antioxidant capacity.
a P values represent paired-samples t-test.
b P values represent the time  group interaction (computed by analysis of the one-way repeated measures ANOVA).
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Patients with PCOS are susceptible to several aberrations
including metabolic disorders and oxidative stress (Asemi and
Esmaillzadeh, 2015; Asemi et al., 2015). The current study shown
that joint omega-3 fatty acids and vitamin E supplementation for
12 weeks in PCOS women downregulated Lp(a) and Ox-LDL
expression. In agreement with our ﬁndings, in a study by Chen
et al. (2003) was seen that both docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) decreased ox-LDL-induced upregula-
tion of in human coronary artery endothelial cells. Furthermore,
vitamin E ameliorated ox-LDL-induced foam cell macrophagesformation (Huang et al., 2012). Previous genetic and epidemiologic
studies have demonstrated that Lp(a) is as a risk factor for
atherosclerotic diseases such as CHD and stroke (Nordestgaard
et al., 2010; Steinberg and Witztum, 2010; Kamstrup et al., 2011).
Omega-3 fatty acids and vitamin E intake may reduce Lp(a) and Ox-
LDL expression through inhibiting phosphatidylinosinitol 3-kinase
and protein kinase B (PKB) pathway (Chen et al., 2003) and
modulating the activities of oxidative stress-induced NF-kB
pathway (Huang et al., 2012).
Our study demonstrated that omega-3 fatty acids and vitamin E
co-supplementation for 12 weeks in PCOS women had the bene-
ﬁcial effects on lipid proﬁles except HDL-cholesterol levels
compared with the placebo. In agreement with our study, supple-
mentation with 3.5 g/day ﬂaxseed oil for 6 weeks decreased tri-
glycerides levels among PCOS women (Vargas et al., 2011). In
addition, 4 g/day omega-3 fatty acids supplementation signiﬁcantly
decreased serum total- and LDL-cholesterol among PCOS women
for 8 weeks (Mohammadi et al., 2012). Our previous study among
GDM women indicated that 1000 mg omega-3 fatty acids from
ﬂaxseed oil plus 400 IU vitamin E co-supplementation for 6 weeks
led to signiﬁcant differences in serum triglycerides, VLDL-, LDL- and
HDL-cholesterol levels (Taghizadeh et al., 2016). However, no sig-
niﬁcant change in lipid proﬁles was seen following the consump-
tion of combined omega-3 fatty acids from ﬁsh oil and vitamin E
among hemodialysis patients for 12 weeks (Karamali et al., 2016).
Lemos et al. (2012) also reported that taking 2 g/day ﬂaxseed oil
among hemodialysis patients for 4 months did not affect tri-
glycerides concentrations. Supplementation with three different
dosages of tocopherol (100 IU/day, 200 IU/day, and 300 IU/day) for
4 months in women with metabolic syndrome was also associated
with a signiﬁcant decrease in total cholesterol levels, but tri-
glycerides concentrations were unaltered (Wang et al., 2010). Pre-vious studies have demonstrated that hyperandrogenism (Macut
et al., 2013), impaired glucose tolerance, insulin resistance and
ovarian dysfunction (Strowitzki et al., 2002) can result in increased
lipid proﬁles. Altered lipid proﬁles in patients with PCOS may
contribute to an increased risk for cardiovascular diseases and
adiposity (Birdsall et al., 1997). In addition, subjects with PCOS are
prone to oxidative stress induced by hyperglycemia, but this seems
not to be related to the direct effect of hyperinsulinemia during
clamp (Savic-Radojevic et al., 2015). Increased pro- and anti-
oxidative indicators are associated with both insulin resistance
and increased testosterone production (Savic-Radojevic et al.,
Table 5
Adjusted changes in metabolic proﬁle of the patients with polycystic ovary syndrome.
Placebo group (n ¼ 34) Omega-3 fatty acids plus vitamin E group (n ¼ 34) Pa
Triglycerides (mg/dL) 7.5 ± 4.0 21.9 ± 4.0 <0.001
VLDL-cholesterol (mg/dL) 1.5 ± 0.8 4.4 ± 0.8 <0.001
Total cholesterol (mg/dL) 10.0 ± 3.8 18.1 ± 3.8 <0.001
LDL-cholesterol (mg/dL) 8.5 ± 3.7 13.3 ± 3.7 <0.001
HDL-cholesterol (mg/dL) 0.7 ± 0.8 0.2 ± 0.8 0.45
Total-/HDL-cholesterol ratio 0.3 ± 0.1 0.4 ± 0.1 <0.001
TAC (mmol/L) 35.0 ± 19.2 60.3 ± 19.1 0.38
GSH (mmol/L) 41.1 ± 8.7 21.7 ± 8.7 0.12
MDA (mmol/L) 0.2 ± 0.1 0.2 ± 0.1 0.99
FSH (IU/L) 0.5 ± 0.5 0.4 ± 0.5 0.20
LH (IU/L) 1.5 ± 0.5 1.2 ± 1.4 0.89
All values are means± SEs. Values are adjusted for baseline values, age and BMI at baseline.
FSH, follicle-stimulating hormone; GSH, total glutathione; LH, luteinizing hormone; MDA, malondialdehyde; TAC, total antioxidant capacity.
a Obtained from ANCOVA.
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fatty acids and vitamin E on lipid concentrations remain unclear,
but several mechanisms have been proposed in related studies.
Omega-3 fatty acids supplementation may decrease triglycerides
and VLDL-cholesterol levels through reduced jejunal secretion of
apoB-48 by increasing its posttranslational degradation (Levy et al.,
2006), the improved postprandial clearance of chylomicrons
(Harris and Bulchandani, 2006) and decreasing hepatic production
of VLDL-cholesterol (Miyoshi et al., 2014). Increased hepatic of
PPAR-a expression and decreased PPAR-g expression levels in-
crease the utilization of lipids in the liver, which in turn would
result in improved lipid proﬁles (Kim do et al., 2013).
Although worries about the consumption of omega-3 fatty acids
and increased lipid peroxidation have lingered about for some time,
but this study indicated that omega-3 fatty acids plus vitamin E co-
supplementation for 12 weeks in PCOS women resulted in a sig-
niﬁcant increase in plasma TAC and a signiﬁcant decrease in MDA
concentrations compared with the placebo, but unchanged GSH
levels. In line with our ﬁndings, diet supplementation with 3 g/day
omega-3 fatty acids among atherosclerotic patients for 2 months
decreased MDA levels (Hassan Eftekhari et al., 2013). Joint sup-
plementation with 2 g omega-3 fatty acids and 400 IU vitamin E
among patients with T2DM for 12 weeks led to a signiﬁcant in-
crease in TAC and a signiﬁcant decrease in MDA levels (Sarbolouki
et al., 2010). Similar ﬁndings were observed following the supple-
mentation with 400 mg/day vitamin E in subjects with T2DM for 3
months (Shinde et al., 2011), and 600 mg/day vitamin E in patients
with T1DM for 3 months (Gupta et al., 2011) and 2.7 g/day of pure
EPA in overweight subjects with non-alcoholic steatohepatitis for
12months (Tanaka et al., 2008). However, some researchers did not
observe such beneﬁcial effects on biomarkers of oxidative stress.
For example, in a study by Cunnane et al. (1995) was seen no sig-
niﬁcant effect in lipid hydroperoxides concentrations following the
consumption with ﬂaxseed oil among healthy young adults for 4
weeks (Cunnane et al., 1995). In addition, no signiﬁcant change in
lipid peroxidation was observed after omega-3 fatty acids (600 mg
EPA and 400 mg DHA per day) supplementation alone or in asso-
ciationwith 30 mg vitamin E, 60 mg vitamin C and 6mg b-carotene
in judoists for 6 weeks (Filaire et al., 2011). The increase of adipo-
cytes in PCOS have been identiﬁed as a source of proinﬂammatory
cytokines (Tan et al., 2006), which in turn act as a potent stimulator
of the production of ROS and nitrogen species. Furthermore,
NADPH oxidase is the major enzymatic source of free radicals in
PCOS, which result in increased production of superoxide radicals
in response to both hyperglycemia and increased levels of free fatty
acids (Gonzalez et al., 2012). The increase of these components in
PCOS are strongly associated with atherosclerosis and hypertension(Gonzalez et al., 2006). The beneﬁcial effects of combined omega-3
fatty acids and vitamin E supplementation on biomarkers of
oxidative stress might be explained by their impacts on reducing
the mitochondrial ROS production (Capo et al., 2015) and improved
antioxidant defense system (Gupta et al., 2011). Although the ef-
fects of omega-3 fatty acids or vitamin E supplementation
compared with statins, glitazones or other medications on
amelioration of lipid proﬁles, and specially Lp(a) and Ox-LDL are
interesting, to the best of our knowledge, data on these compari-
sons are scarce. Nevertheless, few studies have evaluated the ef-
fects of combined therapy of omega-3-fatty acids with lipid-
lowering agents on lipid proﬁles. For instance, in a study by
Mindrescu et al. (2008) was observed that combined therapy with
omega-3 fatty acids and rosuvastatin compared with only rosu-
vastatin ameliorated lipid proﬁles and endothelial function in
South Asian subjects with dyslipidemia and endothelial dysfunc-
tion. Nonetheless, we believe that further studies are needed about
the effect of omega-3 fatty acids and vitamin E supplementation
compared with lipid-lowering agents on amelioration of lipid
proﬁles in patients with PCOS.
The current study had few limitations. Due to budget limita-
tions, we did not evaluate measurements of fatty acids proﬁles and
vitamin E levels at study baseline and at the end-of-trial. Further-
more, we could not asses omega-3 fatty acids and vitamin E co-
supplementation on expression levels of biomarkers of oxidative
stress. It must be kept in mind that in the current study, we did not
evaluate the effects of omega-3 fatty acids and vitamin E co-
supplementation on fasting plasma glucose, insulin, total testos-
terone and other steroids levels due to limited funding for research
projects in developing countries. Therefore, assessment of these
variables are warranted in future studies.
Overall, omega-3 fatty acids and vitamin E co-supplementation
for 12 weeks in PCOS women signiﬁcantly improved gene expres-
sion of Lp(a) and Ox-LDL, lipid proﬁles and biomarkers of oxidative
stress.
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